Arcus Biosciences, Inc.
RCUS
$9.16
$0.030.33%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -391.00M | -283.00M | -270.00M | -249.00M | -231.00M |
| Total Depreciation and Amortization | 10.00M | 10.00M | 10.00M | 9.00M | 9.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 59.00M | 81.00M | 81.00M | 82.00M | 82.00M |
| Change in Net Operating Assets | 22.00M | 22.00M | 21.00M | -89.00M | -70.00M |
| Cash from Operations | -300.00M | -170.00M | -158.00M | -247.00M | -210.00M |
| Capital Expenditure | -3.00M | -6.00M | -11.00M | -20.00M | -25.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 120.00M | -78.00M | -96.00M | -47.00M | -79.00M |
| Cash from Investing | 117.00M | -84.00M | -107.00M | -67.00M | -104.00M |
| Total Debt Issued | 47.00M | 47.00M | 47.00M | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 150.00M | 237.00M | 237.00M | 241.00M | 261.00M |
| Repurchase of Common Stock | -7.00M | -7.00M | -2.00M | -1.00M | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 190.00M | 277.00M | 282.00M | 240.00M | 261.00M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 7.00M | 23.00M | 17.00M | -74.00M | -53.00M |